|[November 09, 2012]
IntegenX Announces Issuance of Key Patent for Ambient Temperature Storage of DNA and RNA
PLEASANTON, Calif. --(Business Wire)--
IntegenX reported today that the USPTO has issued U.S. Patent #
8,283,165 to Mike Hogan, Ph.D., and GenVault Corporation, a subsidiary
of IntegenX Inc. This is a fundamental patent covering formulations to
create a dry state matrix for ambient temperature preservation of RNA
and DNA. While significant advances in high-throughput sequencing have
been made in recent years, technologies for sample storage and transport
have not enjoyed the same breakthroughs. IntegenX provides GenTegra®
DNA and GenTegra RNA as chemical matrices that protect samples from
hydrolysis, oxidation and microbial destruction. The GenTegra products
allow scientists to collect, transport and store their samples
indefinitely and safely at ambient temperatures. Further, GenTegra has
been shown to protect DNA and RNA at temperature extremes - from -80 °C
to 76 °C - that might be encountered during unrefrigerated
"Since the acquisition of GenVaut Corporation by IntegenX in 2011, we
have continued to develop products to help customers ensure the
integrity of their precious samples for forensics, next generation
sequencing, cancer research and for biological investigation," said
Stevan Jovanovich, President and Chief Executive Officer of IntegenX.
"IntegenX is delighted that the USPTO has recognized the novel and
unique character of GenTegra in granting this key patent to Dr. Hogan
and GenVault Corporation."
About IntegenX Inc.
IntegenX, headquartered in Pleasanton, California, is a leading
developer of rapid human DNA identification technology, next-gen
sequencing library preparation, and DNA/RNA ambient temperature
stability and storage products. IntegenX technology platforms are the
result of the integration of advanced fluidics, optics, and biochemistry
capabilities to produce products for DNA-based human identity testing
and forensics, next generation sequencing and biodefense applications.
The company's expertise and extensive intellectual property includes its
patented MOVe™ valve technology, patent-pending PrepX™ reagent kits for
next generation sequencing library preparation, as well as a portfolio
of patented reagents for DNA and RNA preservation including GenTegra®
for stabilization and storage of purified DNA and RNA, and GenPlate®
for storage of blood samples. For more information, please visit www.integenx.com.
IntegenX, the IntegenX logo, PrepX, GenTegra and GenPlate are
trademarks of IntegenX Inc.
All other names and trademarks are the property of their respective
[ Back To Technology News's Homepage ]